

JC06 Rec'd PTO 26 AUG 2005

PCT #4

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,

ON August 23, 2005

Russell H. Halata

Name of Person Mailing the Document

August 23, 2005

DATE



Attorney Docket No. P51355

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Douglas P. NESTA

Serial No.: 10/519,033

Group Art Unit No.: Unknown

Filed: July 2, 2002

Examiner: Unknown

For: "A Novel Stable Formulation"

Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and
Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those documents already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.


Attorney Docket No. 131355
Serial No.: 10/519,033

Statement of Certification. The undersigned hereby certifies either:

(a) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

(b) that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Statement.


Respectfully submitted,



Andrea V. Lockenour
Attorney for Applicants
Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7568
Facsimile (610) 270-5090

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51355	INTERNATIONAL APPLICATION NO. 10/519,033
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Douglas Nesta	
		PRIORITY FILING DATE 2 July 2002	GROUP



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	6,171,586	9 Jan. 2001	Lam, <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
BA	WO97/04801	13 Feb. 1997	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	"Cantuzumab Mertansine ImmunoGen, SmithKline Beecham US FDA accepts IND," <i>R&D Focus Drug News</i> (October 4, 1999) <i>World Publications Ltd.</i> , ISSN: 1350-1135
CB	Smith, S., "Technology Evaluation: C242-DM1, ImmunoGen Inc.," <i>Current Opinion in Molecular Therapeutics</i> (2001) 3(2):198-203 (XP-008011026.)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.